Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Dotan I, Levy-Nissenbaum E, Chowers Y, Fich A, Israeli E, Adar T, Shteingart S, Soreq H, Goldin E.

Dig Dis Sci. 2016 Nov;61(11):3246-3254. Epub 2016 Aug 29.


Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010).

Levy-Nissenbaum E, Thio HB, Burstein P, Thaci D.

Br J Dermatol. 2015 Jul;173(1):247-9. doi: 10.1111/bjd.13623. Epub 2015 May 26. No abstract available.


Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery.

Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC.

Sci Transl Med. 2013 Nov 27;5(213):213ra167. doi: 10.1126/scitranslmed.3007049.


Pharmacokinetic and efficacy study of cisplatin and paclitaxel formulated in a new injectable poly(sebacic-co-ricinoleic acid) polymer.

Levy-Nissenbaum E, Khan W, Pawar RP, Tabakman R, Naftali E, Winkler I, Kaufman O, Klapper L, Domb AJ.

Eur J Pharm Biopharm. 2012 Sep;82(1):85-93. doi: 10.1016/j.ejpb.2012.06.004. Epub 2012 Jun 23.


Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection.

Xiao Z, Levy-Nissenbaum E, Alexis F, Lupták A, Teply BA, Chan JM, Shi J, Digga E, Cheng J, Langer R, Farokhzad OC.

ACS Nano. 2012 Jan 24;6(1):696-704. doi: 10.1021/nn204165v. Epub 2012 Jan 3.


In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Gaidukov L, Bar D, Yacobson S, Naftali E, Kaufman O, Tabakman R, Tawfik DS, Levy-Nissenbaum E.

BMC Clin Pharmacol. 2009 Nov 17;9:18. doi: 10.1186/1472-6904-9-18.


HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.

Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK, Farokhzad OC.

ChemMedChem. 2008 Dec;3(12):1839-43. doi: 10.1002/cmdc.200800122. No abstract available.


Nanotechnology and aptamers: applications in drug delivery.

Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC.

Trends Biotechnol. 2008 Aug;26(8):442-9. doi: 10.1016/j.tibtech.2008.04.006. Epub 2008 Jun 19. Review.


Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.

Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC.

Nano Lett. 2007 Oct;7(10):3065-70. Epub 2007 Sep 14.


Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.

Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC.

Biomaterials. 2007 Feb;28(5):869-76. Epub 2006 Oct 20.


Confirmation of the association between male pattern baldness and the androgen receptor gene.

Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E.

Eur J Dermatol. 2005 Sep-Oct;15(5):339-40.


Clinical manifestations in Israeli cystinuria patients and molecular assessment of carrier rates in Libyan Jewish controls.

Sidi R, Levy-Nissenbaum E, Kreiss Y, Pras E.

Isr Med Assoc J. 2003 Jun;5(6):439-42. Erratum in: Isr Med Assoc J. 2010 Aug;12(8):515. Isr Med Assoc J. 2010 Jul;12(7):452. Kreiss I [corrected to Kreiss,Y].


Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN encoding corneodesmosin.

Levy-Nissenbaum E, Betz RC, Frydman M, Simon M, Lahat H, Bakhan T, Goldman B, Bygum A, Pierick M, Hillmer AM, Jonca N, Toribio J, Kruse R, Dewald G, Cichon S, Kubisch C, Guerrin M, Serre G, Nöthen MM, Pras E.

Nat Genet. 2003 Jun;34(2):151-3.


Megalencephalic leukoencephalopathy with subcortical cysts; a founder effect in Israeli patients and a higher than expected carrier rate among Libyan Jews.

Ben-Zeev B, Levy-Nissenbaum E, Lahat H, Anikster Y, Shinar Y, Brand N, Gross-Tzur V, MacGregor D, Sidi R, Kleta R, Frydman M, Pras E.

Hum Genet. 2002 Aug;111(2):214-8. Epub 2002 Jul 16.


Genetic analysis of Brugada syndrome in Israel: two novel mutations and possible genetic heterogeneity.

Levy-Nissenbaum E, Eldar M, Wang Q, Lahat H, Belhassen B, Ries L, Friedman E, Pras E.

Genet Test. 2001 Winter;5(4):331-4.


A missense mutation in the LIM2 gene is associated with autosomal recessive presenile cataract in an inbred Iraqi Jewish family.

Pras E, Levy-Nissenbaum E, Bakhan T, Lahat H, Assia E, Geffen-Carmi N, Frydman M, Goldman B, Pras E.

Am J Hum Genet. 2002 May;70(5):1363-7. Epub 2002 Mar 26.


A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel.

Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M.

Am J Hum Genet. 2001 Dec;69(6):1378-84. Epub 2001 Oct 25.


A gene causing autosomal recessive cataract maps to the short arm of chromosome 3.

Pras E, Pras E, Bakhan T, Levy-Nissenbaum E, Lahat H, Assia EI, Garzozi HJ, Kastner DL, Goldman B, Frydman M.

Isr Med Assoc J. 2001 Aug;3(8):559-62.


Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21.

Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, Kastner DL, Goldman B, Pras E.

Circulation. 2001 Jun 12;103(23):2822-7.


A nonsense mutation (W9X) in CRYAA causes autosomal recessive cataract in an inbred Jewish Persian family.

Pras E, Frydman M, Levy-Nissenbaum E, Bakhan T, Raz J, Assia EI, Goldman B, Pras E.

Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3511-5.


Supplemental Content

Loading ...
Support Center